Futura Medical plc – Award of CSD500 CE mark

Futura Medical plc – Award of CSD500 CE mark

Futura Medical plc, the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce the award of the CE mark certificate to Reckitt Benckiser plc for CSD500, the Company's novel condom. The award of the CE mark means that CSD500 can be marketed in 29 European countries and also in a number of non-European territories that recognise the CE mark process.  Exclusive worldwide rights to CSD500 are licensed to Reckitt Benckiser plc.

CSD500 is clinically proven to produce a firmer erection and increase penile size in healthy men whilst wearing a condom during sexual intercourse and give women a longer lasting sexual experience.

CSD500's intellectual property position has been protected throughout the world, including the principal consumer markets in Europe, the USA and Canada, through patents now granted or proceeding to grant in 36 countries with one remaining application pending.

James Barder, Futura's Chief Executive, said: "The award of the CE mark for CSD500 is a highly significant event in the development of Futura. We look forward to working with Reckitt Benckiser to commercialise CSD500 and to Futura becoming a revenue generating company with a recurring royalty income stream."

A Reckitt Benckiser spokesperson said: "CSD500 is an exciting innovation and we are delighted that the CE mark has been awarded.  We are actively evaluating plans to launch a product with CSD500 in the near future."

No Comments

Post a Comment